Agios Pharmaceuticals
AGIO
99 hedge funds and large institutions have $1.08B invested in Agios Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 37 increasing their positions, 20 reducing their positions, and 12 closing their positions.
208% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 12
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
85% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 20
34% more capital invested
Capital invested by funds: $804M → $1.08B (+$277M)
34% more funds holding
Funds holding: 74 → 99 (+25)
61% less call options, than puts
Call options by funds: $569K | Put options by funds: $1.46M
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$59.1M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$41.6M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$32.5M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$31.1M |
| 5 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$20.6M |
Top Sellers
AGIO Hedge Fund Activity: Q2 2014 in Review
99 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q2 2014, worth a combined $1.08B — up 34% from $804M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new AGIO positions and 12 closed out — a net gain of 25 holders — while 37 added to existing stakes and 20 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $59.1M. The largest seller was Flagship Ventures 2007 General Partner, cutting an estimated $78.7M.
- 99 institutional investors held Agios Pharmaceuticals (AGIO) as of Q2 2014, up from 74 in Q1 2014.
- Funds reported $1.08B of Agios Pharmaceuticals stock for Q2 2014, up 34% quarter-over-quarter.
- 37 funds opened new Agios Pharmaceuticals positions in Q2 2014 and 12 closed out, a net change of +25 holders.
- The largest Agios Pharmaceuticals buyer in Q2 2014 was Fidelity Investments, an estimated $59.1M added.
- The largest Agios Pharmaceuticals seller in Q2 2014 was Flagship Ventures 2007 General Partner, an estimated $78.7M sold.
Based on aggregated 13F filings for Q2 2014.